tbuckley/cabot-search huggingface dataset:
CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention
Authors: Colleen Isabelle, Amy Boles, Kathleen McConnell, Robyn Keller, Rachel Burzinski, Zachary Hutchins, Giulia Calabretto, Lara Cheslow, Jonathan Xu, Nitin Chakravarti, Pierluigi Porcu, Neda Nikbakht, Anjali Mishra
Journal: Leukemia (2025)

Abstract Cutaneous T-Cell Lymphoma (CTCL) is a non-Hodgkin’s lymphoma involving malignant skin-homing T-cells, characterized by variable severity and limited treatment options. Our study shows that patient samples and derived cell lines express CD38 on CTCL cells, and αCD38 antibodies effectively target CD38 in a mouse model. In vivo αCD38 antibody treatment led to the loss of CD38 expression in residual tumor cells, highlighting the need for innovative strategies to improve CTCL outcomes despite the CD38 loss in residual tumor cells. To investigate the role of CD38 in CTCL pathology, we used CRISPR-Cas9 to create CD38-deficient (CD38 KO ) CTCL cells. These CD38 KO cells showed higher expression of oncogenes B-catenin , TCF7 , and BCL6 , along with reduced migration. Elevated NAD+ levels in CD38 KO cells increased cellular respiration after CD38 inhibition in CD38 WT cells. In vivo, CD38 KO cell transplants led to more aggressive tumors, likely due to elevated β-catenin, Bcl6, and Tcf-1 signaling. Prior research in multiple myeloma showed αCD38 antibody efficacy relies on CD38 expression. We discovered that panobinostat, a histone deacetylase inhibitor, increased surface CD38 expression in CTCL cells dose-dependently. Combining panobinostat with αCD38 antibody in a CTCL mouse model significantly improved survival compared to the antibody alone, underscoring CD38’s therapeutic potential in CTCL.
Regulatory plasticity of the human genome
Authors: Jaya Srivastava, Ivan Ovcharenko
Journal: Molecular Biology and Evolution (2025)

Abstract Evolutionary turnover in non-coding regions has driven phenotypic divergence during past speciation events and continues to facilitate environmental adaptation through variants. We used a deep learning model to identify the substrates of regulatory turnover using genome wide mutations mimicking three evolutionary pathways: recent history (human-chimp substitutions), modern population (human population variation), and mutational susceptibility (random mutations). We observed enhancer turnover in approximately 6% of the whole genome, with more than 80% of the novel activity arising from repurposing of enhancers between cell-types. Frequency of turnover in a cell-type is remarkably similar across the three pathways, despite only ∼19% overlap in the source regions. The majority of turnover loci were found to be localized within 100kb of a gene, with the highest turnover occurring near neurodevelopmental genes including CNTNAP2, NPAS3, and AUTS2. Flanking enhancers of these genes undergo high turnover irrespective of the mutational model pathway, suggesting a high plasticity in neurocognitive evolution. Based on susceptibility to random mutations, these enhancers were identified as vulnerable by nature and feature a higher abundance of cell type-specific transcription factor binding sites (TFBSs). Our findings suggest that enhancer repurposing within vulnerable loci drives regulatory innovation while keeping the core regulatory networks intact.
Global and regional causes of maternal deaths 2009–20: a WHO systematic analysis
Authors: Jenny A Cresswell, Monica Alexander, Michael Y C Chong, Heather M Link, Marija Pejchinovska, Ursula Gazeley, Sahar M A Ahmed, Doris Chou, Ann-Beth Moller, Daniel Simpson, Leontine Alkema, Gemma Villanueva, Yanina Sguassero, Özge Tunçalp, Qian Long, Shaoming Xiao, Lale Say
Journal: The Lancet Global Health (2025)
Diagnostic, research, and real-life effect of the 2023 EULAR−ACR classification criteria for antiphospholipid syndrome
Authors: Karen Schreiber, Silvia Aguilera, Olga Amengual, Hannah Cohen, Danieli Castro Oliveira De Andrade, Alí Duarte-García, Maria Gerosa, Catherine Nelson-Piercy, Massimo Radin, Luigi Raio, Savino Sciascia
Journal: The Lancet Rheumatology (2025)
Enhancer binding as a KEysTONE of fasting response
Authors: Nathaniel F. Henneman, Ganna Panasyuk
Journal: Trends in Endocrinology and Metabolism (2025)

Fasting is a recurrent daily energy stress that benefits healthspan and lifespan. While ketones fuel fasting in vertebrates, the underlying transcriptional mechanism remains incompletely understood. Recently, Korenfeld et al. revealed peroxisome proliferator-activated receptor alpha (PPARα)-dependent enhancer priming as a keystone for ketone production, increasing our understanding of mechanisms underlying metabolic benefits of alternate-day fasting (ADF).
Tailoring hyaluronic acid hydrogels: Impact of cross-linker length and density on skin rejuvenation as injectable dermal fillers and their potential effects on the MAPK signaling pathway suppression
Authors: Mohanapriya Murugesan, Ramya Mathiyalagan, Zelika Mega Ramadhania, Jinnatun Nahar, Cuong Hung Luu, V H Giang Phan, Deok Chun Yang, Qihui Zhou, Se Chan Kang, Thavasyappan Thambi
Journal: Bioactive Materials (2025)
CAR T Cell Therapy for Glioblastoma: A Review of the First Decade of Clinical Trials
Authors: Sabrina L Begley, Donald M O'Rourke, Zev A Binder
Journal: Molecular Therapy (2025)

Glioblastoma (GBM) is an aggressive primary brain tumor with a poor prognosis and few effective treatment options. Focus has shifted towards using immunotherapies, such as chimeric antigen receptor (CAR) T cells, to selectively target tumor antigens and mediate cytotoxic activity within an otherwise immunosuppressive tumor microenvironment. Between 2015-2024, the results of eight completed and two ongoing phase I clinical trials have been published. The majority of studies have treated recurrent GBM patients, although the inter- and intra-patient tumor heterogeneity has been historically challenging to overcome. Molecular targets have included EGFR, HER2, and IL13Rα2 and there has been continued development in improving receptor constructs, identifying novel targets, and adding adjuvant enhancers to increase efficacy. CAR T cells have been safely administered through both peripheral and locoregional routes but with variable clinical and radiographic efficacy. Most trials utilized autologous T cell products to avoid immune rejection yet were unable to consistently show robust engraftment and persistence within patients. Nonetheless, targeted immunotherapies such as CAR T cell therapy remain the next frontier for GBM treatment, and the popularity and complexity of this undertaking is evident in the past, present, and future landscape of clinical trials.
Real-World Effectiveness and Safety of Upadacitinib in Crohn’s disease: A Multi-Centre Study
Authors: Jalpa Devi, Anthony Xu, Molly Stone, Anish Patel, Abdul Khan, Nikhil Reddy, Jeremy Klein, Navreet Chowla, Caroline Benson, Bryan Christopher Luu, Katherine Huang, Fnu Jaiprada, Marc Fenster, Ryan Ungaro, Joel Pekow, Amanda M Johnson, Andres J Yarur, Richa Shukla, Julia Huecker, Shrinivas Bishu, Parakkal Deepak
Journal: Clinical Gastroenterology and Hepatology (2025)

We aimed to describe the real-world effectiveness and safety of upadacitinib (UPA), an oral Janus kinase 1 inhibitor (JAKi) in patients with Crohn's disease (CD). A retrospective analysis was conducted across nine centers in the United States, focusing on adults with CD treated with UPA 45 mg as induction therapy for active luminal disease. The co-primary endpoints were clinical remission at 12 weeks (Harvey Bradshaw Index ≤ 4 or absence of symptoms on physician's global assessment) and endoscopic remission at 6 months (SEMA-CD score of 0-1 or absence of ulcers). Secondary outcomes included clinical, radiographic and histologic outcomes, and adverse events (AEs). The study included 334 CD patients (median age 34 years and disease duration 12 years, and 44.6% female). Clinical remission was achieved in 52.1% at 12 weeks and 55.9% at 6 months. Endoscopic remission at 6 months was observed in 42.7% of patients. Advanced therapy (AT)-naive patients achieved a higher proportion of clinical remission at 12 weeks (58.6%) and 6 months (97.7%) compared to patients with one prior AT (53.3% and 66.7%) and two or more prior AT exposures (50.2% and 40.5%), respectively. BMI and longer disease duration was associated with lower odds of clinical remission at 12 weeks. AEs were reported in 13.5% and UPA discontinued in 19.1%. UPA was effective at inducing clinical and endoscopic remission in a real-world group of patients with CD, even with prior exposure to multiple prior advanced therapies. No new safety concerns were identified.
Pro-Inflammatory Microglia-Targeted Peptide Therapy Ameliorates Neonatal Hypoxic-Ischemic Encephalopathy in Mice
Authors: Rika Zen, Shunichiro Tsuji, Maeda Tomoko, Makoto Urushitani, Takashi Murakami, Tomoya Terashima
Journal: Molecular Therapy (2025)

Neonatal hypoxic-ischemic encephalopathy is aggravated by intracerebral inflammation. As pro-inflammatory microglia in the brain become activated in this condition, we aimed to establish a novel peptide therapy for neonatal hypoxic-ischemic encephalopathy by investigating the therapeutic effects of pro-inflammatory microglial depletion. MG1 homing peptide, which selectively targets and binds pro-inflammatory microglia, was conjugated with the pro-apoptotic peptide D[KLAKLAK]2 (KLA), creating MG1-KLA. After confirming that MG1-KLA selectively bound pro-inflammatory microglia and decreased cell viability by inducing apoptosis in a dose-dependent manner, the in vivo therapeutic effect of MG1-KLA was assessed following intracerebroventricular injection in hypoxic-ischemic encephalopathy model mice through histological, behavioral, and biochemical analyses. In these mice, MG1-KLA selectively bound to microglia and induced their apoptosis. Brain atrophy was significantly suppressed in the mice treated with MG1-KLA compared with non-treated mice. Additionally, motor function and locomotor hyperactivity were improved in mice treated with MG1-KLA compared with non-treated mice. Gene expression analysis further revealed that pro-inflammatory cytokine expression was downregulated in mice treated with MG1-KLA compared with non-treated mice. These findings suggest that the novel MG1-KLA peptide therapy has high potential for treating neonatal patients with hypoxic-ischemic encephalopathy through the selective induction of apoptosis in pro-inflammatory microglia.
Myeloma cell intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy
Authors: Shuangshuang Yang, Guixiang Wang, Jiahuan Chen, Wu Zhang, Jing Wu, Weiqing Liu, Ling Bai, Peide Huang, Jianqing Mi, Jie Xu
Journal: Molecular Therapy (2025)

Multiple myeloma (MM) relapse still occurs after a durable response to anti-BCMA chimeric antigen receptor-engineered T (CAR-T) cell therapy with less-defined factors. Herein, we investigated a CAR-T-exposed MM patient who relapsed after 12 months of remission by single-cell transcriptome sequencing. The bone marrow CAR-T population at relapse exhibited exhaustion and proliferation attenuation. The recurrent myeloma cells were deficient in or weakly expressed TNFRSF17 (BCMA) but possessed an identical immunoglobulin clonality to the baseline tumor. Interestingly, combined with the transcriptome profile of the myeloma strains, MM cells with BCMA negativity featured high ANXA1 expression that was identified as an inferior prognostic indicator for MM patients. At a single-cell resolution, BCMA-negative myeloma could be present in the MM patients without CAR-T cell exposure and displayed an increased level of intrinsic ANXA1 transcripts. In vitro assays unveiled that ANXA1 elevation conferred growth capacity to BCMA-negative myeloma cells via AMPKα signaling activation and disturbed CAR-T cell fitness. Blockade of ANXA1 reduced BCMA-negative myeloma cell proliferation. Murine models further demonstrated that ANXA1 inhibition could effectively diminish BCMA-negative myeloma that escaped from CAR-T's attack. Together, our data identified ANXA1 as a potential target for BCMA-negative myeloma clearance. The ANXA1-targeting strategy might be helpful to CAR-T treatment optimization.
Novel insights into taxane pharmacology: an update on drug resistance mechanisms, immunomodulation and drug delivery strategies
Authors: Giovanni Luca Beretta, Giuliana Cassinelli, Giacomina Rossi, Amalia Azzariti, Iléana Corbeau, Diego Tosi, Paola Perego
Journal: Drug Resistance Updates (2025)

Taxanes are effective in several solid tumors. Paclitaxel, the main clinically available taxane, was approved in the early nineties, for the treatment of ovarian cancer and later on, together with the analogs docetaxel and cabazitaxel, for other malignancies. By interfering with microtubule function and impairing the separation of sister cells at mitosis, taxanes act as antimitotic agents, thereby counteracting the high proliferation rate of cancer cells. The action of taxanes goes beyond their antimitotic function because their main cellular targets, the microtubules, participate in multiple processes such as intracellular transport and cell shape maintenance. The clinical efficacy of taxanes is limited by the development of multiple resistance mechanisms. Among these, extracellular vesicles have emerged as new players. In addition, taxane metronomic schedules shows an impact on the tumor microenvironment reflected by antiangiogenic and immunomodulatory effects, an aspect of growing interest considering their inclusion in treatment regimens with immunotherapeutics. Preclinical studies have paved the bases for synergistic combinations of taxanes both with conventional and targeted agents. A variety of drug delivery strategies have provided novel opportunities to increase the drug activity. The ability of taxanes to orchestrate different cellular effects amenable to modulation suggests novel options to improve cures in lethal malignancies.
Overcoming cancer therapy resistance: From drug innovation to therapeutics
Authors: Jin-Rui Wei, Meng-Yi Lu, Tian-Hua Wei, Joshua S Fleishman, Hui Yu, Xiao-Li Chen, Xiang-Tu Kong, Shan-Liang Sun, Nian-Guang Li, Ye Yang, Hai-Wen Ni
Journal: Drug Resistance Updates (2025)
TGFβ-activated Asporin interacts with STMN1 to promote prostate cancer docetaxel chemoresistance and metastasis by upregulating the Wnt/β-catenin signaling pathway
Authors: Shengdong Ge, Jinpeng Cen, Xiaofeng Liu, Yaying Hong, Yuting Tang, Yuzhong Yu, Haolin Li, Tao Xie, Chong Wang, Maoping Cai, Yang Qiu, Xianzi Zeng, Tianming Peng, Qu Li, Qianyi Li, Xingcheng Wu, Xian-Lu Song, Shan-Chao Zhao
Journal: Drug Resistance Updates (2025)
Hippocampal Sclerosis: A Review on Current Research Status and Its Mechanisms
Authors: Ting Zhao, Xiaoxiao Cui, Xinru Zhang, Mengke Zhao, Yousef Rastegar-Kashkooli, Junyang Wang, Qiang Li, Chao Jiang, Nan Li, Fei Xing, Na Xing, Junmin Wang, Jian Wang
Journal: Ageing Research Reviews (2025)
Use of CD19-targeted Immune Modulation to Eradicate AAV Neutralizing Antibodies
Authors: Bhavya S. Doshi, Caroline A. Markmann, Noelle Novak, Silvia Juarez Rojas, Robert Davidson, Julia Q. Chau, Wei Wang, Sean Carrig, Cristina Martos Rus, Benjamin J. Samelson-Jones, Juliana C. Small, Vijay G. Bhoj, Lindsey A. George
Journal: Molecular Therapy (2025)
Evaluating Patient’s Ability to Detect Changes in Hair Density Using Standardized Global Scalp Photography: A Cross-Sectional Study
Authors: Christina S Oh, Nnaemeka Anyanwu, Michael G Buontempo, Deesha Desai, Ambika Nohria, Jerry Shapiro, Kristen Lo Sicco
Journal: Journal of the American Academy of Dermatology (2025)
“Weibing” in traditional Chinese medicine—biological basis and mathematical representation of disease-susceptible state
Authors: Wanyang Sun, Rong Wang, Shuhua Ouyang, Wanli Liang, Junwei Duan, Wenyong Gong, Lianting Hu, Xiujuan Chen, Yifang Li, Hiroshi Kurihara, Xinsheng Yao, Hao Gao, Rongrong He
Journal: Acta Pharmaceutica Sinica B (2025)
Endotypes of Atopic Dermatitis
Authors: Nanna Fyhrquist, Ying Yang, Piia Karisola, Harri Alenius
Journal: Journal of Allergy and Clinical Immunology (2025)

Atopic dermatitis (AD) is a chronic, heterogeneous skin condition driven by a combination of genetic, immune, and environmental factors. The original classification into extrinsic and intrinsic endotypes has proven overly simplistic. Recent research into the varied immune profiles and molecular signatures of AD has revealed distinct endotypes - subtypes defined by specific biological processes rather than visible symptoms alone. These endotypes encompass classifications based on immune pathways, including Th2-dominant, Th1, Th17/Th22-driven responses, genetic factors, and microbial interactions. Recognizing these endotypes has become essential for advancing personalized treatments, as each subtype responds differently to immune-modulating therapies. Current treatment options, such as moisturizers, immunosuppressants, and biologics, show varied efficacy across AD endotypes, underscoring the need for more precise, endotype-specific approaches. Emerging molecular profiling technologies offer promising avenues to identify distinct biomarkers, refining AD classification and paving the way for more targeted treatments and improved patient outcomes.
Intranodal injection of neoantigen-bearing engineered Lactococcus lactis triggers epitope spreading and systemic tumor regressions
Authors: Junmeng Zhu, Yi Sun, Xiaoping Qian, Lin Li, Fangcen Liu, Xiaonan Wang, Yaohua Ke, Jie Shao, Lijing Zhu, Lifeng Wang, Qin Liu, Baorui Liu
Journal: Acta Pharmaceutica Sinica B (2025)
Anti-CD19 CAR-T cell therapy for acquired hemophilia A
Authors: Christian R. Schultze-Florey, Felicitas R. Thol, Krasimira Aleksandrova, Kalin Stoyanov, Rodrigo Gutierrez Jauregui, Lubomir Arseniev, Jana Leise, Stephan Klöß, Florian H. Heidel, Andreas Tiede
Journal: Leukemia (2025)
T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC
Authors: Margo I. Orlen, William P. Vostrejs, Rina Sor, Jayne C. McDevitt, Samantha B. Kemp, Il-Kyu Kim, Adam B. Kramer, Nataliya Tovbis Shifrin, Nune Markosyan, Cynthia Clendenin, Mallika Singh, Elsa Quintana, Marie Menard, Robert H. Vonderheide, Ben Z. Stanger
Journal: Cancer Discovery (2025)

Abstract Activating mutations in KRAS drive tumorigenesis in pancreatic ductal adenocarcinoma (PDAC), promoting tumor cell proliferation and contributing to an immunosuppressive tumor microenvironment (TME) rendering PDAC tumors insensitive to immunotherapy. RAS(ON) multi-selective inhibitors, such as daraxonrasib (RMC-6236) and RMC-7977, target the active state of RAS, with potent anti-tumor activity in PDAC murine models. Here, we report that RAS(ON) multi-selective inhibition led to rapid and profound PDAC regressions in immunocompetent mice, decreasing myeloid cells and increasing T cells and macrophages in the TME. The depth and duration of tumor regression depended on T cells and conventional dendritic cells. Moreover, the combination of RAS(ON) multi-selective inhibitors with immunotherapy conferred deeper and more durable tumor regressions, including complete responses not seen with either treatment alone. In summary, concurrent inhibition of mutant and wild-type RAS is active in concert with T cell immunotherapy, revealing RAS(ON) multi-selective inhibitors as a potential therapeutic immuno-sensitizing strategy in PDAC.
Wearable transdermal drug delivery system controlled by wirelessly powered acoustic waves
Authors: Jikai Zhang, Feixuan Yang, Haimeng Wu, Hui Ling Ong, Peter Arnold, Meng Zhang, Yunhong Jiang, Duygu Bahar, Zhishan Yuan, Xin Yang, Yong-Qing Fu
Journal: Journal of Controlled Release (2025)
Enhancing immunogenicity and release of in situ-generated tumor vesicles for autologous vaccines
Authors: Jin-Hu Chen, Cai-Li Zhao, Jing Zhang, Jia-Wen Cheng, Jian-Ping Hu, Pei Yu, Ming-Hua Yang, Yuan-Zheng Xia, Yong Ying, Zhen-Zhen Zhang, Jian-Guang Luo, Ling-Yi Kong, Chao Zhang
Journal: Journal of Controlled Release (2025)
Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk
Authors: Steven J Yakubov, Nicolas M Van Mieghem, Jae K Oh, Saki Ito, Kendra J Grubb, Daniel O'Hair, John K Forrest, Hemal Gada, Mubashir Mumtaz, G Michael Deeb, Gilbert H L Tang, Joshua D Rovin, Renuka Jain, Stephan Windecker, Kimberly A Skelding, Neal S Kleiman, Stanley J Chetcuti, Alexandra Dedrick, Sarah Verdoliva Boatman, Jeffrey J Popma, Michael J Reardon
Journal: Journal of the American College of Cardiology (2025)
Exosomal delivery of rapamycin modulates blood-brain barrier penetration and VEGF axis in glioblastoma
Authors: Lin Lin Song, Yong Pei Tang, Yuan Qing Qu, Yun Xiao Yun, Rui Long Zhang, Cai Ren Wang, Vincent Kam Wai Wong, Hui Miao Wang, Meng Han Liu, Li Qun Qu, Jian Hui Wu, Hang Hong Lo, Betty Yuen Kwan Law
Journal: Journal of Controlled Release (2025)
Statistical review: frequently given comments updated
Authors: Stian Lydersen
Journal: Annals of the Rheumatic Diseases (2025)

From 2006 to 2024, I have carried out statistical reviews of about 700 manuscripts for Annals of the Rheumatic Diseases and RMD open. My most frequent review comments concern the following: 1. Report how missing data were handled. 2. Limit the number of covariates in regression analyses. 3. Do not use stepwise selection of covariates. 4. Validate prediction models. 5. Adjust for baseline values in randomised controlled trials. 6. Do not adjust for baseline values in observational studies. 7. Dichotomising a continuous variable can be a bad idea. 8. Student t test is better than nonparametric tests. 9. Mean (SD) are also relevant for nonnormally distributed data. 10. Adjusting P values for multiplicity. 11. Report estimate, CI, and (possibly) P value-in that order of importance. 12. Do not test for baseline imbalances in a randomised controlled trial. 13. Format for reporting CIs. 14. Mind the number of reported decimal places. 15. Report absolute numbers where relevant.
Stimuli-responsive polymer-dasatinib prodrug to reprogram cancer-associated fibroblasts for boosted immunotherapy
Authors: Yuxin Zhang, Jie Zhou, Yiyan Wang, Yaping Wu, Yunkun Li, Bing Wang, Guohao Liu, Qiyong Gong, Kui Luo, Jing Jing
Journal: Journal of Controlled Release (2025)
Modulating lipid metabolism by nanoparticles (NPs)-mediated ACSL3 silencing to inhibit hepatocellular carcinoma growth and metastasis
Authors: Linzhuo Huang, Rui Xu, Siyu Chen, Chunhao Lin, Wende Li, Senlin Li, Phei Er Saw, Lei Zhang, Xiaoding Xu
Journal: Molecular Cancer (2025)
Mixed Adenoneuroendocrine Carcinoma of the Common Bile Duct With Solitary Lymph Node Metastasis Revealed on 18F-FDG PET/CT
Authors: Huan Liang, Minghao Gao, Guoxing Zhao, Lingge Wei, Peng Xie
Journal: Clinical Nuclear Medicine (2025)

Mixed adenoneuroendocrine carcinoma of the common bile duct is extremely rare. A 72-year-old man presented with jaundice for 1 week. 18 F-FDG PET/CT showed intense 18 F-FDG uptake in the common bile duct and adjacent lymph node. Finally, postoperative pathology confirmed the diagnosis of mixed adenoneuroendocrine carcinoma of the common bile duct with solitary lymph node metastasis.
Surface-coated silica microparticles: In vitro and ex vivo evaluation of a preclinical extended release platform conceived for intravitreal injection
Authors: Marco Block, Achim Grube, Achim Göpferich, Christoph Saal, Blessing C Ilochonwu, Álvaro Cárcamo-Martínez, Grazia Giorgio, Remko A Bakker, Richard Deanne, Joachim Schäfer, Brennan Walder, Roman Simon
Journal: Journal of Controlled Release (2025)
Preclinical evaluation of several polymeric micelles identifies Soluplus®-docetaxel as the most effective candidate in multiple glioblastoma models
Authors: Júlia German-Cortés, Raquel Herrero, Natalia Torroglosa, Alexandra Pumarola, Narine Fischer-Albiol, Sofia Campos-Moreno, Sofia Sabaté, Àngels Alcina, Sandra Mancilla, Belén García, Monserrat Llaguno-Munive, Zamira V Diaz-Riascos, Cláudia Martins, Simó Schwartz, Roser Ferrer Costa, Ibane Abasolo, Pilar Sánchez-Gomez, Bruno Sarmento, Diana Rafael, Fernanda Andrade
Journal: Journal of Controlled Release (2025)